Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Stock Up More Than 9 Percent Since CFO Announced Resignation Yesterday

NEW YORK, Dec. 9 (GenomeWeb News) - Shares in Orchid Biosciences were up 6.13 percent at $11.94 in mid-afternoon trading one day after the company announced that CFO Mike Spicer has resigned.

 

In all, the shares have climbed 9.5 percent since Orchid made the announcement on Wednesday.

Orchid said Spicer, who is also senior vice president of finance at the firm, said he plans to join a publicly traded biopharmaceutical company. The company has promoted Joseph Warusz to vice president of financial planning and analysis, and has given him "additional financial oversight" until a replacement for Spicer has been found.

 

In the same statement, Orchid reiterated its revenue expectation of about $60 million for the fourth quarter.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.